Market Overview:
The global CAR T-cell immunotherapy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, technological advancements in CAR T-cell therapy, and rising funding for CAR T-cell therapy research. The global CAR T-cell immunotherapy market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into monotherapy and combination therapy. On the basis of application, the market is segmented into hematologic malignancies and solid malignancies. The hematologic malignancies segment dominates this market owing to high prevalence rates for blood cancers across regions.
Product Definition:
CAR T-cell immunotherapy is a treatment that uses genetically modified cells from the patient's own body to fight cancer. The cells, called CAR T-cells, are modified to include a gene that directs them to attack cancer cells. CAR T-cell immunotherapy is important because it can effectively treat cancers that have resisted other treatments.
Monotherapy:
Monotherapy is a treatment method that involves the administration of one drug or vaccine for the prevention and/or treatment of a disease. Monotherapy can be used in cases where there are no other drugs or vaccines available for the treatment of a particular disease. In most cases, monotherapy is used as an adjuvant therapy along with some combination therapies to enhance its efficacy.
The major factor responsible for market growth includes increasing adoption due to lack of effective treatments.
Combination Therapy:
Combination therapy is a technique where more than one drug or medication is used together to treat a particular disease. In this therapy, the drugs or medications are used in combination with each other as they work on similar molecular targets and produce additive effects which enhances their therapeutic action.
In cancer treatment, combination therapies include chemotherapy and radiation therapy, which are some of the most common forms of treatment provided by oncologists.
Application Insights:
The application segment is segregated into hematologic malignancies, solid tumors and other applications. Among these, the hematologic malignancies segment dominated the overall market in terms of revenue share in 2017. This can be attributed to increasing incidence rates of blood cancer such as myeloma and lymphoma across the globe. For instance, according to data published by LLS Hematology Products & Services Inc., a total of 5480 new cases were registered in 2016 for leukemia/lymphatic disorders and 3400 new cases were registered for myeloma across the U.S.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased funding for research and development activities, and high adoption of immunotherapy treatment methods. In addition, increasing incidence rates of cancer has led to an increase in demand for immunotherapies that target CAR-T cells for treating various cancers.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising investments by governments as well as private companies in order to boost R&D capabilities pertaining to cell therapy products and clinical trials involving these products. Moreover, a large patient pool with hematological or solid tumor malignancy is also contributing towards regional growth. For instance, China outbound medical tourism has witnessed a significant rise due its favorable government initiatives such as tax benefits on cancer treatments offered by Chinese government agencies such as The Cancer Administration (TCA) & Tumorregeneration Therapy Center (CRT).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the CAR T-cell immunotherapy market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for CAR T-cell immunotherapy products over the forecast period.
- Rising awareness about CAR T-cell therapy: The rising awareness about CAR T-cell therapy among patients and healthcare professionals is another major factor driving growth in this market. With increasing clinical evidence supporting its efficacy, more patients are opting for this treatment option over traditional therapies such as chemotherapy and radiation therapy which often have severe side effects associated with them. This is expected to result in robust growth prospects for the CAR T-cell immunotherapy market over the next few years
Scope Of The Report
Report Attributes
Report Details
Report Title
CAR T-Cell Immunotherapy Market Research Report
By Type
Monotherapy, Combination Therapy
By Application
Hematologic Malignancies, Solid Malignancies
By Companies
AbbVie, Celgene, Kite Pharma, Oxford BioMedica, Novartis, Gilead, Pfizer, Cellectis, Bellicum, Mustang Bio, CARsgen Therapeutics, Xyphos, Minerva Biotechnologies, Adaptimmune, Ziopharm Oncology, Aurora Biopharma, Creative Biolabs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
176
Number of Tables & Figures
124
Customization Available
Yes, the report can be customized as per your need.
Global CAR T-Cell Immunotherapy Market Report Segments:
The global CAR T-Cell Immunotherapy market is segmented on the basis of:
Types
Monotherapy, Combination Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hematologic Malignancies, Solid Malignancies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Celgene
- Kite Pharma
- Oxford BioMedica
- Novartis
- Gilead
- Pfizer
- Cellectis
- Bellicum
- Mustang Bio
- CARsgen Therapeutics
- Xyphos
- Minerva Biotechnologies
- Adaptimmune
- Ziopharm Oncology
- Aurora Biopharma
- Creative Biolabs
Highlights of The CAR T-Cell Immunotherapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monotherapy
- Combination Therapy
- By Application:
- Hematologic Malignancies
- Solid Malignancies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CAR T-Cell Immunotherapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CAR T-Cell Immunotherapy is a treatment for cancer that uses the patientu2019s own immune cells to fight the cancer. These cells are called CAR T-cells, or u201cchimeric antigen receptoru201d T-cells.nnCAR T-cell therapy works by helping the body's natural defenses identify and attack tumors. Once these tumor cells are identified, CAR T-cells can destroy them by recognizing and attacking specific proteins on their surface. This therapy has been shown to be effective in treating many types of cancers, including leukemia, lymphoma, and multiple myeloma.
Some of the key players operating in the car t-cell immunotherapy market are AbbVie, Celgene, Kite Pharma, Oxford BioMedica, Novartis, Gilead, Pfizer, Cellectis, Bellicum, Mustang Bio, CARsgen Therapeutics, Xyphos, Minerva Biotechnologies, Adaptimmune, Ziopharm Oncology, Aurora Biopharma, Creative Biolabs.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CAR T-Cell Immunotherapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CAR T-Cell Immunotherapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CAR T-Cell Immunotherapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CAR T-Cell Immunotherapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CAR T-Cell Immunotherapy Market Size & Forecast, 2018-2028
4.5.1 CAR T-Cell Immunotherapy Market Size and Y-o-Y Growth
4.5.2 CAR T-Cell Immunotherapy Market Absolute $ Opportunity
Chapter 5 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 CAR T-Cell Immunotherapy Market Size Forecast by Type
5.2.1 Monotherapy
5.2.2 Combination Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 CAR T-Cell Immunotherapy Market Size Forecast by Applications
6.2.1 Hematologic Malignancies
6.2.2 Solid Malignancies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CAR T-Cell Immunotherapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America CAR T-Cell Immunotherapy Analysis and Forecast
9.1 Introduction
9.2 North America CAR T-Cell Immunotherapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America CAR T-Cell Immunotherapy Market Size Forecast by Type
9.6.1 Monotherapy
9.6.2 Combination Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America CAR T-Cell Immunotherapy Market Size Forecast by Applications
9.10.1 Hematologic Malignancies
9.10.2 Solid Malignancies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe CAR T-Cell Immunotherapy Analysis and Forecast
10.1 Introduction
10.2 Europe CAR T-Cell Immunotherapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe CAR T-Cell Immunotherapy Market Size Forecast by Type
10.6.1 Monotherapy
10.6.2 Combination Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe CAR T-Cell Immunotherapy Market Size Forecast by Applications
10.10.1 Hematologic Malignancies
10.10.2 Solid Malignancies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific CAR T-Cell Immunotherapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Type
11.6.1 Monotherapy
11.6.2 Combination Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Applications
11.10.1 Hematologic Malignancies
11.10.2 Solid Malignancies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America CAR T-Cell Immunotherapy Analysis and Forecast
12.1 Introduction
12.2 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Type
12.6.1 Monotherapy
12.6.2 Combination Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Applications
12.10.1 Hematologic Malignancies
12.10.2 Solid Malignancies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Type
13.6.1 Monotherapy
13.6.2 Combination Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Applications
13.10.1 Hematologic Malignancies
13.10.2 Solid Malignancies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CAR T-Cell Immunotherapy Market: Competitive Dashboard
14.2 Global CAR T-Cell Immunotherapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Celgene
14.3.3 Kite Pharma
14.3.4 Oxford BioMedica
14.3.5 Novartis
14.3.6 Gilead
14.3.7 Pfizer
14.3.8 Cellectis
14.3.9 Bellicum
14.3.10 Mustang Bio
14.3.11 CARsgen Therapeutics
14.3.12 Xyphos
14.3.13 Minerva Biotechnologies
14.3.14 Adaptimmune
14.3.15 Ziopharm Oncology
14.3.16 Aurora Biopharma
14.3.17 Creative Biolabs
